CB07-Exatecan

• Description :

  CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. ADC conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research[1].

• UNSPSC :

  12352203

• Target :

  Drug-Linker Conjugates for ADC; Topoisomerase

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cb07-exatecan.html

• Purity :

  98.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming)

• Smiles :

  O=C(C=CC1=O)N1CC(N[C@@H](CCNC(CCOCCOCCOCCOCCOCCOCCOCCOC)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC(C=C2)=CC=C2COC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O

• Molecular Formula :

  C71H94FN11O22

• Molecular Weight :

  1472.56

• References & Citations :

  [1]Weijia Tang, et al. Method for treating her2-positive solid tumor. Patent WO2023198079A1.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• Isoform :

  Camptothecins

• CAS Number :

  [2879247-31-9]